A Precarious Union: Combining Proprietary and Generic Businesses
The major generics companies, flush with cash from the recent plethora of patent expirations, are all forging ahead in the proprietary business in order to boost margins and even out the volatile revenues and earnings inherent in their core business. They're pursuing, by and large, strategies that don't take them far from their core expertise and involve reformulating known compounds. Some companies have had moderate success, but weaving together two such disparate businesses is a challenge.
by Wendy Diller
The news would have been music to any company's ears: sales of glatiramer acetate (Copaxone) are likely to bring revenues...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.